We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

C4XD C4x Discovery Holdings Plc

-0.325 (-3.80%)
19 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
C4x Discovery Holdings Plc LSE:C4XD London Ordinary Share GB00BQQ2RV18 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.325 -3.80% 8.225 1,024,803 16:35:06
Bid Price Offer Price High Price Low Price Open Price
8.00 8.45 8.05 8.00 8.05
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 1.71M -11.11M -0.0441 -1.81 20.18M
Last Trade Time Trade Type Trade Size Trade Price Currency
16:36:16 O 75,000 8.25 GBX

C4x Discovery (C4XD) Latest News

C4x Discovery (C4XD) Discussions and Chat

C4x Discovery Forums and Chat

Date Time Title Posts
19/4/202411:11C4X Discovery Holdings plc3,136
03/1/202408:46c4xd Astra Zeneca $11m Milestone payment3

Add a New Thread

C4x Discovery (C4XD) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type

C4x Discovery (C4XD) Top Chat Posts

Top Posts
Posted at 19/4/2024 09:20 by C4x Discovery Daily Update
C4x Discovery Holdings Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker C4XD. The last closing price for C4x Discovery was 8.55p.
C4x Discovery currently has 252,227,097 shares in issue. The market capitalisation of C4x Discovery is £20,178,168.
C4x Discovery has a price to earnings ratio (PE ratio) of -1.81.
This morning C4XD shares opened at 8.05p
Posted at 15/4/2024 22:07 by davemac3
well that's it, vote for taking private confirmed. What are folks doing with their shares? I have some in an iweb ISA and will probably get them out as a share certificate. I also have some in a HL SIPP which I may leave there for now but move them eventually to a SIPP provider that deals with asset match.
Posted at 09/4/2024 13:02 by takeiteasy
9 April 2024 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, was informed on 8 April 2024 that Clive Dix, Executive Chairman of the Company, purchased 485,320 ordinary shares of 0.01 pence each ("Ordinary Shares") in the Company at a price of 10.3 pence per share.

Following this purchase of shares, Clive Dix has a beneficial interest in 2,071,809 Ordinary Shares, representing approximately 0.82 per cent. of the Company's issued share capital.

nice timing :) lols
Posted at 04/4/2024 19:18 by takeiteasy
help me with HLare they saying they will nip in and sell behind your back if you do nothing and hold at a price they achieve ?i see them stopping new purchases of illiquid stock but selling at this level when they can be held - very odd
Posted at 02/4/2024 08:20 by takeiteasy
and following on from what you are saying they wiill no doubt squeeze the last of the forced sellers down to whatever price it takes (who knows 7/6/5 they can make up any number they want) - i can stay in my SIPP for 5 years if needs be so to sell at 8p which is about 15% of analyst suggested value is beyond the pail as they say !no advice intended etc
Posted at 27/3/2024 20:47 by timbo003

"Best option will be to short these since could be 0p when they delisted."

I suspect that if you were to go short and the company delists, the counterparty to your spreadbet would want you to deliver the shares when the bet expires. Not an easy task if they are delisted, although I note that the RNS states that the directors intend to set up a matched bargain facility following delisting, if they do, you would have to wait for a willing seller to come along before you could buy shares and the offer price then could be quite a bit higher than it is now 😮
Posted at 27/3/2024 07:58 by nigelpm
So the announcement will see share price fall materially further - ironic!
Posted at 06/1/2024 06:54 by takeiteasy
UPDATE: Dr Julie Simmonds at Panmure Gordon commented: “C4XD has received an $11m milestone payment from AstraZeneca. We update our estimates. The payment, in addition to the divestment of the Orexin programme in July which generated £16m, means we expect the company to end the year (July) with Net Cash of £22m, the current market capitalization. C4XD is very good value with a strong drug development engine; there are few companies which have successfully developed and out-licensed three differentiated products. We reiterate our BUY recommendation.̶1;

Posted at 05/1/2024 14:41 by mirabeau
DM - today

It’s fair to say C4X Discovery had a fantastic start with the shares advancing 113 per cent over the foreshortened trading week after drug giant AstraZeneca delivered an $11million post-Christmas windfall.

It came in the form of what the experts call a ‘milestone payment’ under a $402million deal with Anglo-Swedish giant, which has licensed the right to NRF2 activator, created by C4XD to tackle chronic respiratory disease.

Analysts said the payment went further than adding a material sum to the AIM company’s coffers – it provided third-party validation of the technology.

'We see this as an important value inflexion which should reinvigorate sentiment in the share,' said regional broker Shore Capital.

'Moreover, this serves as a timely reminder that C4XD has licensing deals in place with some of the leading developers for its programmes.'
Posted at 03/1/2024 11:39 by intoodeep
News of C4X Discovery Holdings PLC (AIM:C4XD)’s latest payment from AstraZeneca PLC (LSE:AZN) solidifies and validates the company’s place as a skilled drug developer, analysts have said.

Following the firm’s update that US$11 million had been received under a deal worth up to US$400 million with AstraZeneca for the NRF2 activator programme, Shore Cap analysts backed aim-listed C4X.

“We see this as an important value inflection which should reinvigorate sentiment in the share,” the bank said in a note.

“Moreover, this serves as a timely reminder that C4XD has licensing deals in place with some of the leading developers for its programmes.”

The deal included an initial upfront payment of US$2 million to C4X and consisted of a series of developmental and commercial milestones.

Under this, C4X’s NRF2 activator programme has been out-licensed to AstraZeneca with the goal of creating an oral therapy for inflammatory and respiratory diseases.

Shore Cap added that its model for C4X suggested fair value of 52p per share, marking a prospective 480% increase on Tuesday’s closing value of 8.7p.

“These agreements serve as strong validation of C4XD’s prowess in drug discovery and demonstrate its ability to distil value from assets early in the development process,” the bank said.

Indeed, the market reacted positively to the news, with shares in C4X climbing 37% to 11.98p following the news on Wednesday morning.
Posted at 09/12/2023 17:25 by golden prospect
Something very interesting in play, on radar.

From AR2022 "During November 2020 £15.0 million (before expenses) was raised via a placing of 99,169,286 ordinary shares and an open offer for 7,973,572 ordinary shares at 14 pence each. In addition, 99,169,286 warrants were issued over ordinary shares, exercisable at 28p per share with an exercise period of 5 years."

Clearly an easy short from 2022 @ 45p

Stock is tight, Richard Griffiths 22.07%, Polar Capital 17.84%, Lombard Odier 17.29 (have been increasing), Baillie Gifford 8.52%, Canaccord Genuity Wealth Mgt 4.54%, Calculus Capital 3.63%, Herald Investment Mgt 2.67

76.56% accounted for, guess small float leads to distorted share price.

Someone ready/building to make an offer ?
C4x Discovery share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock